Aripiprazole Tablet
Product Images NDC 70518-2820

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 70518-2820). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A line graph comparing the proportion of relapse over time between Aripiprazole and placebo groups. The x-axis shows days from randomization up to 182 days, while the y-axis displays the proportion with relapse from 0 to 1. Two lines represent Aripiprazole (solid blue) and placebo (dashed red). The graph also includes the number of subjects at risk listed below the x-axis at various time points.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A Kaplan-Meier curve chart illustrating the proportion of subjects with relapse over 364 days from randomization in a study comparing Aripiprazole and placebo. The chart includes lines representing relapse proportions for Aripiprazole (solid line) and placebo (dashed line), with a table below showing the number of subjects at risk at various time points for each group.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' depicting the fold change relative to reference for AUC and Cmax values with various drugs including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam). Horizontal error bars indicate 90% confidence intervals.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A chart depicting the fold change and 90% confidence interval in pharmacokinetic parameters such as Cmax and AUC for various drugs, including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram, relative to a reference without interacting drug exposure.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' displaying changes in AUC and Cmax relative to reference across various conditions including CYP2D6 metabolizer status, gender, age, hepatic impairment, and severe renal impairment. The chart uses horizontal bars with error bars to represent fold changes and confidence intervals.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A forest plot chart illustrating the fold change and 90% confidence intervals of dehydro-aripiprazole pharmacokinetics. It compares variables such as CYP2D6 metabolism status, gender, age, hepatic impairment, and severe renal impairment against a reference, showing changes in AUC and Cmax values.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart illustrating the fold change and 90% confidence intervals for Aripiprazole's area under the curve (AUC) and maximum concentration (Cmax) when co-administered with various inhibitors and inducers. The graph compares changes relative to a reference without interacting drugs, including CYP3A4 and CYP2D6 inhibitors, a CYP3A4 inducer, gastric acid blockers, and other drugs such as valproate, lithium, and lorazepam.*

FDA Label Image

Remedy_label (Remedy Label)

Aripiprazole 10 mg tablet packaging label showing quantity of 30 tablets. Label includes NDC number 70518-2820-00, manufacturer Ascend Labs, LLC in Montvale, NJ, and repackager RemedyRepack Inc., Indiana, PA. Directions refer to package insert; storage instructions specify 20-25°C with permitted excursions. Contains warning to keep medication out of reach of children.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure of Aripiprazole showing its molecular framework with chlorinated aromatic rings, a piperazine moiety, and other characteristic groups.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier survival curve chart comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis shows days from randomization (0 to 182 days), and the y-axis shows the proportion with relapse (0 to 1.0). Aripiprazole has a lower relapse proportion than placebo over time. A table below the graph shows the number of subjects at risk for each group at selected time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.